Wiedenroth, Christoph B.
Pruefer, Diethard
Adameit, Miriam S. D.
Mayer, Eckhard
Guth, Stefan
Article History
Accepted: 2 March 2023
First Online: 25 April 2023
Change Date: 27 May 2023
Change Type: Update
Change Details: The second sentence in the abstract should have read ‘Currently, three specific treatmentmodalities are available: pulmonary endarterectomy, balloon pulmonary angioplasty, and targeted medical therapy.’ instead of ‘Currently, three specific treatmentmodalities are available: pulmonary endarterectomy, pulmonary balloon angioplasty, and targeted medical therapy.’
Declarations
:
: C.B. Wiedenroth has received speaker fees and/or consultant honoraria from Actelion, AOP Orphan Pharmaceuticals AG, Bayer AG, BTG, MSD, OrphaCare GmbH, and Pfizer. D. Pruefer has received speaker fees and/or consultant honoraria from AstraZeneca, Johnson&Johnson, and Bayer AG. E. Mayer has received speaker fees and/or consultant honoraria from Actelion, Janssen, Bayer AG, and MSD. S. Guth has received speaker fees and/or consultant honoraria from Actelion, Bayer AG, MSD, and Pfizer. M.S. D. Adameit declares that she has no competing interests.
: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.